Navigation Links
China Pharma Holdings, Inc. Appoints The Ruth Group
Date:10/21/2008

Leading IR Consultancy for Emerging Chinese Companies

HAIKOU CITY, Hainan, China, Oct. 21 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which develops, manufactures, and markets generic and branded bio-pharmaceutical products in China, today announced the appointment of The Ruth Group (TRG) as its investor relations agency.

Ms. Zhilin Li, President and CEO of China Pharma Holdings, Inc., commented, "We look forward to working with The Ruth Group as our strategic, full-service investor relations team to enhance the visibility of China Pharma Holdings among the U.S. investment community. The Ruth Group's dedicated focus and expertise within the biopharmaceuticals industry has contributed to its successful track record providing top tier investor relations and public relations counsel for China-based, and healthcare companies. We will partner with TRG to position ourselves as China's premier biopharmaceutical company with a profitable low-cost, high margin business model and diverse, expanding product portfolio driven by the market demands of our region's rapidly growing healthcare industry."

Ms. Carol Ruth, President of The Ruth Group, stated, "We welcome the opportunity to partner with China Pharma Holdings to raise the Company's profile in the U.S. as we have done for emerging Chinese companies, including Sinovac, JA Solar, SINA, and China TechFaith Wireless. Our strategic messages will highlight China Pharma Holdings as a compelling investment opportunity for U.S. value investors looking for profitable biopharmaceutical companies with substantial growth potential. Our location in New York City allows us to maintain close contact with the U.S. healthcare investment community and ensures that our clients meet their information requirements. In addition, our professional staff understands how to close the information gap and be available in Asian time zones to service our clients."

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc., develops, manufactures, and markets specialty pharmaceutical products in China that treat a wide range of conditions, including cardiovascular and CNS diseases, infections, digestive diseases and other prevalent diseases. China Pharma Holdings Inc., is registered in Delaware, USA. Hainan Helpson Bio-pharmaceutical Co., Ltd (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .

About The Ruth Group

The Ruth Group (TRG) is a New York City-based full service investor relations and public relations agency providing top-tier counsel, communications strategies and capital markets advisory to emerging healthcare and technology companies. TRG's integrated, targeted outreach efforts leverage the agency's relationships with U.S. investors and media outlets to maximize the impact of positive milestones and enhance visibility for each client. In-depth, sector-specific expertise differentiates TRG from all other agencies through specialized teams dedicated to alternative energy, biopharmaceuticals, healthcare services, internet media, medical technology, and technology. Each team is run by professionals skilled in the areas of finance, corporate communications and science. A broad and growing client base of emerging Chinese clients within each of these sectors demonstrates TRG's success in working through Asian time zones to close the information gap and provide superior service. For more information, please visit http://www.theruthgroup.com .

Safe Harbor Statement: Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

For more information, please contact:

China Pharma Holdings, Inc.

Diana Huang

Tel: +86-898-6681-1730

Email: hps@chinapharmaholdings.com

The Ruth Group

Sara Ephraim

Tel: +1-646-536-7002

Email: sephraim@theruthgroup.com


'/>"/>
SOURCE China Pharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CFO of China Yingxia Emphasizes Growth in Organic and Health Food Segment in Interview by The Wall Street Transcript
2. Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of Chinas Ministry of Science and Technology
3. China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million
4. China Bio Energy Holdings Group Announces Financing and Exercise of Warrants
5. China-Biotics, Inc. Retains KPMG for the Implementation of Sarbanes-Oxley Act Section 404
6. China Biologic Products Enters Into Agreement to Acquire 35% Interest in Xian Huitian Blood Products Co., Ltd. and Introduces Preliminary Guidance for 2009
7. China-Biotics, Inc. Approved to List on the Nasdaq Global Market
8. China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance
9. China Medicine to Showcase Bethin Weight Loss Product at 2008 Natural Products Expo East Trade Show
10. China Yingxia International, Inc. Announces $2 Million Share Repurchase Program
11. China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):